financetom
Business
financetom
/
Business
/
Bain Capital invests $157 mln in Indonesia's Mayapada Healthcare Group
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bain Capital invests $157 mln in Indonesia's Mayapada Healthcare Group
Dec 11, 2024 5:34 PM

SINGAPORE, Dec 12 (Reuters) - U.S.-based private

investment firm Bain Capital has invested $157 million in

Indonesian private healthcare company Mayapada Healthcare Group,

or Sejahteraraya Anugrahjaya Tbk PT, according to a

joint statement on Thursday.

The companies said the investment, made via Bain Capital's

special situations strategy, will be used to further expand

Mayapada's hospital operations via organic and strategic growth

initiatives.

Bain Capital's special situations team uses a combination of

credit and equity strategy and has more than $20 billion in

assets under management.

The investment marks Bain Capital's first in Indonesia,

Southeast Asia's biggest economy.

Southeast Asian healthcare assets are gaining favour as

global investors bet on the region's growing affluence and aging

population and the sector's ability to weather the current

challenging economic environment.

"Indonesia faces a growing gap between healthcare supply and

demand due to demographic shifts like an aging population and

rising affluence," said Jonathan Tahir, Mayapada's chairman and

Group CEO, in the statement.

Bain Capital's partner and special situations head of Asia,

Sarit Chopra, said the firm had "deep conviction" about

Mayapada's continued growth as the private healthcare market in

Indonesia is just beginning to develop.

Founded in 2008, Mayapada operates seven private hospitals

across Indonesia, including a flagship hospital in south

Jakarta, with more than 1,000 beds, according to the statement.

It has several projects in the pipeline and plans to operate

more than 2,000 beds by 2027, the statement showed.

Shares of the company have surged 747% year-to-date,

according to LSEG data.

The transaction is targeted to close in early 2025, subject

to regulatory and public shareholders approval, the statement

said.

($1 = 4.4300 ringgit)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CN Rail Advancing Decarbonization Efforts with EMD Mainline Hybrid Locomotive From Progress Rail
CN Rail Advancing Decarbonization Efforts with EMD Mainline Hybrid Locomotive From Progress Rail
Apr 5, 2024
07:41 AM EDT, 04/05/2024 (MT Newswires) -- CN Rail (CNR.TO) -- which will issue first-quarter 2024 financial and operating results after market close on April 23, 2024 -- announced Friday that it has purchased its first hybrid diesel-battery electric mainline locomotive from Progress Rail, a Caterpillar Company, as part of its decarbonization plans. The EMD will be tested to understand...
Chevron Insider Sold Shares Worth $448,252, According to a Recent SEC Filing
Chevron Insider Sold Shares Worth $448,252, According to a Recent SEC Filing
Apr 5, 2024
07:37 AM EDT, 04/05/2024 (MT Newswires) -- Alana K Knowles, VP and Controller, on April 02, 2024, sold 2,800 shares in Chevron ( CVX ) for $448,252. Following the Form 4 filing with the SEC, Knowles has control over a total of 12,302 shares of the company, with 276 shares held directly and 12,026 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/93410/000112760224012509/xslF345X03/form4.xml...
CI Financial Reports Final Results of Substantial Issuer Bid
CI Financial Reports Final Results of Substantial Issuer Bid
Apr 5, 2024
07:37 AM EDT, 04/05/2024 (MT Newswires) -- CI Financial Corp. ( CIXXF ) , which slipped 1.1% in Canada yesterday, on Friday reported the final results of its substantial issuer bid. Under the bid, the company bought for cancellation about 4.9 million of its common shares at the purchase price of $17.50 per share for about $85 million. Shares purchased...
AstraZeneca Says Phase 3 Trial of Imfinzi Shows Positive Results in Meeting Primary Endpoints
AstraZeneca Says Phase 3 Trial of Imfinzi Shows Positive Results in Meeting Primary Endpoints
Apr 5, 2024
07:42 AM EDT, 04/05/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that a phase 3 trial of Imfinzi showed positive high-level results and clinically meaningful improvement in the study's primary endpoints of overall survival and progression-free survival in patients with limited-stage small-cell lung cancer who had not progressed following concurrent chemoradiotherapy. The 737 trial patients were randomized to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved